Atlas Trials

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

Clinical trial NCT02970162 · COMPLETED

Trial details

NCT number
NCT02970162
Sponsor
Catalyst Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Lambert-Eaton Myasthenic Syndrome
Start date
2016-11-01
Primary completion
2017-10-01
Enrollment
26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.